{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:04:04Z","timestamp":1776405844217,"version":"3.51.2"},"reference-count":6,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.bulcan.2022.10.004","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T07:49:46Z","timestamp":1668066586000},"page":"168-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["5-fluorouracil with oxaliplatin and\/or irinotecan for advanced sinonasal intestinal-type adenocarcinoma (ITAC)"],"prefix":"10.1016","volume":"110","author":[{"given":"Victor","family":"Sarradin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Betrian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9onor","family":"Chaltiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Brac De La Perriere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Pierre","family":"Delord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bulcan.2022.10.004_bib0035","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/hed.24416","article-title":"Intestinal-type sinonasal adenocarcinomas: the road to molecular diagnosis and personalized treatment: intestinal-type sinonasal adenocarcinomas. Eisele DW, editor","volume":"38","author":"Hoeben","year":"2016","journal-title":"Head Neck"},{"issue":"5","key":"10.1016\/j.bulcan.2022.10.004_bib0040","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.oraloncology.2012.12.011","article-title":"Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma","volume":"49","author":"Bossi","year":"2013","journal-title":"Oral Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2022.10.004_bib0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MOO.0000000000000445","article-title":"Intestinal-type adenocarcinoma of the sinonasal tract: an update","volume":"26","author":"Rampinelli","year":"2018","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"24","key":"10.1016\/j.bulcan.2022.10.004_bib0050","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1200\/JCO.2004.05.071","article-title":"Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma","volume":"22","author":"Licitra","year":"2004","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2022.10.004_bib0055","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ctrv.2015.07.004","article-title":"The role of systemic therapy in the management of sinonasal cancer: a critical review","volume":"41","author":"Bossi","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"10212","key":"10.1016\/j.bulcan.2022.10.004_bib0060","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:37:10Z","timestamp":1757792230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122003988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0007455122003988"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.10.004","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"5-fluorouracil with oxaliplatin and\/or irinotecan for advanced sinonasal intestinal-type adenocarcinoma (ITAC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}